Affordable Access

Barriers to participation in HIV drug trials: a systematic review.

Authors
  • Mills, Edward
  • Wilson, Kumanan
  • Rachlis, Beth
  • Griffith, Lauren
  • Wu, Ping
  • Guyatt, Gordon
  • Cooper, Curtis
Type
Published Article
Journal
The Lancet Infectious Diseases
Publisher
Elsevier
Publication Date
Jan 01, 2006
Volume
6
Issue
1
Pages
32–38
Identifiers
PMID: 16377532
Source
Medline
License
Unknown

Abstract

The enrolling of adequate participants into HIV experimental drug trials presents an important challenge. We systematically reviewed the literature to identify barriers and concerns amongst HIV patients to participation in HIV clinical drug trials. We reviewed studies for validity and content, and generated pooled estimates of the frequency with which patients identified particular issues by pooling across studies that presented results as proportions. We included three semi-structured interview studies, two open-ended questionnaires, and nine quantitative studies. Major barriers to participation included fear of side-effects, distrust of researchers, general concerns about research design, interference in everyday life or changes in routine, and social discrimination. Results from the quantitative studies indicated that the most prevalent barriers were as follows: suspicions about the drug itself (53%, 95% CI 24-83%), patients were not informed or believed they were not eligible (38%, 25-50%), and travel or transport obstacles (39%, 21-57%). The findings of this study should aid drug trialists in developing strategies to maximise participation and cooperation in HIV clinical drug trials while adequately informing and protecting prospective participants.

Report this publication

Statistics

Seen <100 times